{"id":"https://openalex.org/W2993341505","doi":null,"title":"Clinical experience with substance P receptor (NK1) antagonists in depression.","display_name":"Clinical experience with substance P receptor (NK1) antagonists in depression.","publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W2993341505","mag":"2993341505","pmid":"https://pubmed.ncbi.nlm.nih.gov/12562140"},"language":"en","primary_location":{"id":"pmid:12562140","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12562140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"K Ranga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"K Ranga","raw_affiliation_strings":["Department of Psychiatry, Duke University Medical Center, Durham, NC 27715, USA. krish001@mc.duke.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Duke University Medical Center, Durham, NC 27715, USA. krish001@mc.duke.edu","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"last","author":{"id":null,"display_name":"R Krishnan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Krishnan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210126298"],"apc_list":null,"apc_paid":null,"fwci":3.5083,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.92416569,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"63 Suppl 11","issue":null,"first_page":"25","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.8657000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.8657000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.1185000017285347,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/substance-p","display_name":"substance P","score":0.9070000052452087},{"id":"https://openalex.org/keywords/nk1-receptor-antagonists","display_name":"NK1 receptor antagonists","score":0.9760000109672546},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.9399999976158142},{"id":"https://openalex.org/keywords/aprepitant","display_name":"aprepitant","score":0.968999981880188},{"id":"https://openalex.org/keywords/compound-a","display_name":"compound A","score":0.9750000238418579},{"id":"https://openalex.org/keywords/anxiety","display_name":"anxiety","score":0.5950000286102295},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.5730000138282776},{"id":"https://openalex.org/keywords/dose-finding-trials","display_name":"dose-finding trials","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C202871150","wikidata":"https://www.wikidata.org/wiki/Q12744608","display_name":"NK1 receptor antagonist","level":5,"score":0.7432308197021484},{"id":"https://openalex.org/C2776533618","wikidata":"https://www.wikidata.org/wiki/Q411041","display_name":"Substance P","level":4,"score":0.7412500381469727},{"id":"https://openalex.org/C2780574406","wikidata":"https://www.wikidata.org/wiki/Q621834","display_name":"Aprepitant","level":4,"score":0.7245872020721436},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5448113083839417},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4955490827560425},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.4921785891056061},{"id":"https://openalex.org/C137130169","wikidata":"https://www.wikidata.org/wiki/Q15316325","display_name":"Tachykinin receptor 1","level":5,"score":0.4863331913948059},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.457559198141098},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.4316443204879761},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42525720596313477},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4247239828109741},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.40495479106903076},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3533909320831299},{"id":"https://openalex.org/C118303440","wikidata":"https://www.wikidata.org/wiki/Q419968","display_name":"Neuropeptide","level":3,"score":0.31769248843193054},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.23342537879943848},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.13048911094665527},{"id":"https://openalex.org/C2780884295","wikidata":"https://www.wikidata.org/wiki/Q575136","display_name":"Antiemetic","level":3,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077608","descriptor_name":"Aprepitant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004987","descriptor_name":"Ethers","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006845","descriptor_name":"Hydrocarbons, Fluorinated","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013373","descriptor_name":"Substance P","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D064729","descriptor_name":"Neurokinin-1 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:12562140","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12562140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"},{"id":"mag:2993341505","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12562140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2052215218","https://openalex.org/W2413370990","https://openalex.org/W1961720483","https://openalex.org/W1980143995","https://openalex.org/W2086779277","https://openalex.org/W2257690182","https://openalex.org/W2001989148","https://openalex.org/W2167110017","https://openalex.org/W2166892357","https://openalex.org/W2117374080"],"abstract_inverted_index":{"Substance":[0],"P":[1],"(SP)":[2],"belongs":[3],"to":[4,226],"the":[5,19,29,35,92,106,111,121,167,170,210,213,238,250,256],"neurokinin":[6],"(NK)":[7],"family":[8],"of":[9,28,55,67,74,94,108,113,164,169,184,191,240,252,258],"neuropeptides":[10],"and":[11,37,77,96,125,133,149,203,243,246],"exerts":[12],"its":[13],"biological":[14],"effects":[15],"via":[16],"interaction":[17],"with":[18,71,85,120,140,143,155,186,193,201,215,229,233],"NK1":[20],"receptor.":[21],"The":[22,188],"SP-NK1":[23,171],"receptor":[24,88,172],"system":[25],"is":[26,206],"one":[27],"best-characterized":[30],"neurotransmitter":[31],"pathways":[32],"in":[33,52,110,129,131,197,220,255],"both":[34],"central":[36,65],"peripheral":[38],"nervous":[39],"systems.":[40],"It":[41],"has":[42],"been":[43],"postulated":[44],"that":[45,136,166,212],"this":[46,78],"pathway":[47,173],"may":[48,174],"have":[49,104,160],"important":[50],"roles":[51],"a":[53,72,162,176],"variety":[54],"centrally":[56],"regulated":[57],"pathophysiologic":[58],"conditions,":[59],"including":[60],"depression.":[61,114,187,259],"In":[62,115],"animal":[63],"models,":[64],"injection":[66],"SP":[68,86],"was":[69],"associated":[70],"series":[73],"anxiety-like":[75],"behaviors,":[76],"response":[79],"could":[80],"be":[81,175],"abolished":[82],"by":[83],"pretreatment":[84],"(NK1)":[87],"antagonists":[89],"(SPAs).":[90],"On":[91],"basis":[93],"these":[95,221,253],"other":[97],"encouraging":[98],"preclinical":[99],"results,":[100],"several":[101],"clinical":[102],"trials":[103,222,232],"examined":[105],"potential":[107],"SPAs":[109,122,194,234],"treatment":[112,180,257],"phase":[116],"2":[117],"trials,":[118],"therapy":[119],"aprepitant":[123,202],"(MK-0869)":[124],"compound":[126,204],"A":[127,205],"resulted":[128],"improvements":[130],"depression":[132],"anxiety":[134],"symptoms":[135],"were":[137,223],"quantitatively":[138],"comparable":[139],"those":[141,153,227],"seen":[142,154],"selective":[144],"serotonin":[145],"reuptake":[146],"inhibitors":[147],"(SSRIs)":[148],"significantly":[150],"greater":[151],"than":[152],"placebo.":[156,230],"These":[157],"positive":[158],"results":[159],"established":[161],"proof":[163],"concept":[165],"inhibition":[168],"potentially":[177],"useful":[178],"novel":[179],"option":[181],"for":[182],"management":[183],"patients":[185,242],"apparent":[189],"lack":[190],"benefit":[192],"versus":[195],"placebo":[196],"subsequent":[198],"dose-finding":[199],"studies":[200],"not":[207],"surprising,":[208],"considering":[209],"fact":[211],"outcomes":[214],"an":[216],"active":[217],"control":[218],"(SSRI)":[219],"also":[224,248],"similar":[225],"observed":[228],"Future":[231],"will":[235,247],"focus":[236],"on":[237],"identification":[239],"appropriate":[241],"drug":[244],"regimens":[245],"define":[249],"role":[251],"agents":[254]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-12-13T00:00:00"}